Plus Therapeutics Appoints Ron Andrews to Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy PSTV?
Source: Newsfilter
- New Board Member: Plus Therapeutics has appointed diagnostics veteran Ron Andrews to its Board of Directors, bringing over 35 years of experience in the diagnostics field, which is expected to have an immediate impact on the company's expansion of CNSide in the U.S. and globally.
- Industry Influence: Andrews' extensive connections are anticipated to help Plus maximize the positive impact of CNSide on patients with central nervous system cancers, thereby enhancing shareholder value and underscoring the company's strategic focus in the cancer diagnostics sector.
- Capitalization Achievements: Throughout his career, Andrews has been instrumental in raising over $600 million for various entities and has led over $15 billion in exits, showcasing his strong influence and resource integration capabilities in the capital markets.
- Technological Outlook: CNSide represents a significant technological advancement that utilizes cerebrospinal fluid to assist physicians in better identifying and managing leptomeningeal metastases, and Andrews' involvement is expected to optimize Plus's strategy and path forward in its diagnostics business.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSTV
Wall Street analysts forecast PSTV stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.230
Low
2.00
Averages
8.00
High
19.00
Current: 0.230
Low
2.00
Averages
8.00
High
19.00
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Plus Therapeutics Approves 1-for-25 Reverse Stock Split
- Reverse Stock Split Approval: Plus Therapeutics' Board of Directors has approved a 1-for-25 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's minimum $1 listing requirement, thereby ensuring the company's continued listing eligibility.
- Capital Structure Change: Post-split, the company's outstanding shares will decrease from approximately 171,550,698 to about 6,862,027 shares, while the par value remains unchanged, which may enhance the company's image in the capital markets.
- Trading Arrangements: The reverse stock split will take effect on April 2, 2026, with the company's stock trading on Nasdaq under a new CUSIP number, and shareholders will receive cash payments for any fractional shares instead of issuing them.
- Shareholder Impact: This split applies uniformly to all shareholders and, while it will not alter their percentage interest in the company, it may influence market perception and investment decisions as the company seeks to boost its stock price.
See More
Plus Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Plus Therapeutics has announced a 1-for-25 reverse stock split effective April 2, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum $1.00 bid price requirement, thereby ensuring continued listing eligibility.
- Outstanding Shares Reduction: This reverse split will reduce the company's outstanding shares from approximately 171.55 million to about 6.86 million, significantly decreasing the share count, which may impact market liquidity and investor confidence in the stock.
- Market Reaction: Following the announcement, Plus Therapeutics' stock price plunged 12.95% in premarket trading to $0.1868, reflecting market concerns about the company's future prospects, which could influence investor decisions.
- Financial Performance: Despite reporting a GAAP EPS of -$0.29, beating estimates by $0.01, and revenue of $5.21 million, exceeding expectations by $0.14 million, the decision for a reverse stock split may overshadow these positive financial indicators.
See More
Plus Therapeutics Appoints Ron Andrews to Board
- New Board Member: Plus Therapeutics has appointed diagnostics veteran Ron Andrews to its Board of Directors, bringing over 35 years of experience in the diagnostics field, which is expected to have an immediate impact on the company's expansion of CNSide in the U.S. and globally.
- Industry Influence: Andrews' extensive connections are anticipated to help Plus maximize the positive impact of CNSide on patients with central nervous system cancers, thereby enhancing shareholder value and underscoring the company's strategic focus in the cancer diagnostics sector.
- Capitalization Achievements: Throughout his career, Andrews has been instrumental in raising over $600 million for various entities and has led over $15 billion in exits, showcasing his strong influence and resource integration capabilities in the capital markets.
- Technological Outlook: CNSide represents a significant technological advancement that utilizes cerebrospinal fluid to assist physicians in better identifying and managing leptomeningeal metastases, and Andrews' involvement is expected to optimize Plus's strategy and path forward in its diagnostics business.
See More
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs
- Economic Impact Analysis: Plus Therapeutics' study indicates that earlier diagnosis and therapeutic management of leptomeningeal metastases (LM) using the CNSide cerebrospinal fluid assay can reduce related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention and improved treatment precision, significantly alleviating the financial burden on patients.
- Clinical Data Support: The research highlights that late-stage LM patients incur median inpatient costs of about $20,000, with total related costs potentially exceeding $100,000 per month, underscoring the critical importance of early detection to lower healthcare expenditures and improve patient outcomes.
- Conference Presentation: The findings will be presented at the ISPOR 2026 Annual Meeting, which gathers global experts in health economics and outcomes research, further promoting the recognition of CNSide's clinical and economic value and facilitating its commercialization in the United States.
- Innovative Treatment Solutions: REYOBIQ, a novel radiotherapy targeting CNS tumors, offers enhanced targeting and safety, currently undergoing multiple clinical trials, demonstrating potential therapeutic advantages for difficult-to-treat cancers, thereby strengthening the company's competitive position in this sector.
See More
Plus Therapeutics Releases 2026 Milestones and Financial Results
- Financial Performance: Plus Therapeutics reported a FY GAAP EPS of -$0.29, beating expectations by $0.01, while revenue of $5.21M, down 10.5% year-over-year, still exceeded forecasts by $0.14M, indicating resilience amid challenges.
- Clinical Trial Progress: The company anticipates reporting optimal dosing and interval data for REYOBIQ in the ReSPECT-LM Phase 2 trial in Q3 2026, laying the groundwork for future clinical applications and enhancing market competitiveness.
- FDA Meeting Arrangement: Plus Therapeutics will complete enrollment in the ReSPECT-GBM Phase 2 trial and conduct an End of Phase meeting with the FDA, aiming to align on pivotal trial design, with data expected in Q4 2026 that could influence future drug approval processes.
- Manufacturing Scale-Up: The company plans to complete the commercial manufacturing scale-up for REYOBIQ and begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial, marking a strategic expansion into pediatric oncology and further strengthening its product portfolio.
See More
Plus Therapeutics Receives AMA Approval for New CPT Code
- CPT Code Approval: The American Medical Association has approved the CPT code X566T for tracking the use of REYOBIQ in recurrent glioblastoma and pediatric brain cancer, marking a significant advancement in market access for this innovative treatment, which is expected to enhance clinical application and reimbursement prospects.
- Clinical Trial Progress: Plus Therapeutics is on track to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting to align on pivotal trial design, demonstrating the company's commitment to advancing clinical research.
- Funding Support: The clinical trials for REYOBIQ are supported by grants from the National Cancer Institute and a $17.6 million three-year grant from the Cancer Prevention & Research Institute of Texas, indicating strong recognition and backing from the research community.
- Market Potential: As a novel radiotherapy, REYOBIQ has the potential to improve treatment outcomes for CNS tumors, particularly where conventional therapies fail, further solidifying the company's market position in this critical area.
See More
Plus Therapeutics Approves 1-for-25 Reverse Stock Split
- Reverse Stock Split Approval: Plus Therapeutics' Board of Directors has approved a 1-for-25 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's minimum $1 listing requirement, thereby ensuring the company's continued listing eligibility.
- Capital Structure Change: Post-split, the company's outstanding shares will decrease from approximately 171,550,698 to about 6,862,027 shares, while the par value remains unchanged, which may enhance the company's image in the capital markets.
- Trading Arrangements: The reverse stock split will take effect on April 2, 2026, with the company's stock trading on Nasdaq under a new CUSIP number, and shareholders will receive cash payments for any fractional shares instead of issuing them.
- Shareholder Impact: This split applies uniformly to all shareholders and, while it will not alter their percentage interest in the company, it may influence market perception and investment decisions as the company seeks to boost its stock price.
See More
Plus Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Plus Therapeutics has announced a 1-for-25 reverse stock split effective April 2, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum $1.00 bid price requirement, thereby ensuring continued listing eligibility.
- Outstanding Shares Reduction: This reverse split will reduce the company's outstanding shares from approximately 171.55 million to about 6.86 million, significantly decreasing the share count, which may impact market liquidity and investor confidence in the stock.
- Market Reaction: Following the announcement, Plus Therapeutics' stock price plunged 12.95% in premarket trading to $0.1868, reflecting market concerns about the company's future prospects, which could influence investor decisions.
- Financial Performance: Despite reporting a GAAP EPS of -$0.29, beating estimates by $0.01, and revenue of $5.21 million, exceeding expectations by $0.14 million, the decision for a reverse stock split may overshadow these positive financial indicators.
See More
Plus Therapeutics Appoints Ron Andrews to Board
- New Board Member: Plus Therapeutics has appointed diagnostics veteran Ron Andrews to its Board of Directors, bringing over 35 years of experience in the diagnostics field, which is expected to have an immediate impact on the company's expansion of CNSide in the U.S. and globally.
- Industry Influence: Andrews' extensive connections are anticipated to help Plus maximize the positive impact of CNSide on patients with central nervous system cancers, thereby enhancing shareholder value and underscoring the company's strategic focus in the cancer diagnostics sector.
- Capitalization Achievements: Throughout his career, Andrews has been instrumental in raising over $600 million for various entities and has led over $15 billion in exits, showcasing his strong influence and resource integration capabilities in the capital markets.
- Technological Outlook: CNSide represents a significant technological advancement that utilizes cerebrospinal fluid to assist physicians in better identifying and managing leptomeningeal metastases, and Andrews' involvement is expected to optimize Plus's strategy and path forward in its diagnostics business.
See More
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs
- Economic Impact Analysis: Plus Therapeutics' study indicates that earlier diagnosis and therapeutic management of leptomeningeal metastases (LM) using the CNSide cerebrospinal fluid assay can reduce related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention and improved treatment precision, significantly alleviating the financial burden on patients.
- Clinical Data Support: The research highlights that late-stage LM patients incur median inpatient costs of about $20,000, with total related costs potentially exceeding $100,000 per month, underscoring the critical importance of early detection to lower healthcare expenditures and improve patient outcomes.
- Conference Presentation: The findings will be presented at the ISPOR 2026 Annual Meeting, which gathers global experts in health economics and outcomes research, further promoting the recognition of CNSide's clinical and economic value and facilitating its commercialization in the United States.
- Innovative Treatment Solutions: REYOBIQ, a novel radiotherapy targeting CNS tumors, offers enhanced targeting and safety, currently undergoing multiple clinical trials, demonstrating potential therapeutic advantages for difficult-to-treat cancers, thereby strengthening the company's competitive position in this sector.
See More
Plus Therapeutics Releases 2026 Milestones and Financial Results
- Financial Performance: Plus Therapeutics reported a FY GAAP EPS of -$0.29, beating expectations by $0.01, while revenue of $5.21M, down 10.5% year-over-year, still exceeded forecasts by $0.14M, indicating resilience amid challenges.
- Clinical Trial Progress: The company anticipates reporting optimal dosing and interval data for REYOBIQ in the ReSPECT-LM Phase 2 trial in Q3 2026, laying the groundwork for future clinical applications and enhancing market competitiveness.
- FDA Meeting Arrangement: Plus Therapeutics will complete enrollment in the ReSPECT-GBM Phase 2 trial and conduct an End of Phase meeting with the FDA, aiming to align on pivotal trial design, with data expected in Q4 2026 that could influence future drug approval processes.
- Manufacturing Scale-Up: The company plans to complete the commercial manufacturing scale-up for REYOBIQ and begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial, marking a strategic expansion into pediatric oncology and further strengthening its product portfolio.
See More
Plus Therapeutics Receives AMA Approval for New CPT Code
- CPT Code Approval: The American Medical Association has approved the CPT code X566T for tracking the use of REYOBIQ in recurrent glioblastoma and pediatric brain cancer, marking a significant advancement in market access for this innovative treatment, which is expected to enhance clinical application and reimbursement prospects.
- Clinical Trial Progress: Plus Therapeutics is on track to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting to align on pivotal trial design, demonstrating the company's commitment to advancing clinical research.
- Funding Support: The clinical trials for REYOBIQ are supported by grants from the National Cancer Institute and a $17.6 million three-year grant from the Cancer Prevention & Research Institute of Texas, indicating strong recognition and backing from the research community.
- Market Potential: As a novel radiotherapy, REYOBIQ has the potential to improve treatment outcomes for CNS tumors, particularly where conventional therapies fail, further solidifying the company's market position in this critical area.
See More
